First prescription for COSELA (trilaciclib) issued in China

China as a land mass graphic

Simcere Pharmaceutical Group Limited and G1 Therapeutics Inc., have announced a significant milestone in the fight against cancer with the issuance of the first prescription for COSELA (trilaciclib) in China.

COSELA is a first-in-class FDA and NMPA-approved therapy indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer (ES-SCLC). Myelosuppression induced by chemotherapy is a common toxic side effect in the clinical treatment of SCLC. COSELA has been shown to significantly reduce chemotherapy-induced myelosuppression, a common and potentially serious side effect of chemotherapy that can result in decreased white blood cell counts, increased risk of infections, and prolonged hospitalization.

"The issuance of the first prescription for COSELA in China is an important step forward in improving outcomes for cancer patients treated with chemotherapy," said Jack Bailey, CEO of G1 Therapeutics. 

"As a leading pharmaceutical company in China, this approval helps address a huge unmet clinical need in China for an effective solution to decrease the incidence of myelosuppression before it takes place," said Dr. Tang Renhong, PhD,  Simcere. "Furthermore, the availability of COSELA in China in under three years from licensing the drug to prescription for patients is a truly remarkable feat and marks a significant step forward in the fight against cancer and we are proud to be a part of it."

More in Pulmonary
Page 1 of 16
Next Page